419P Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Additional analyses from 4-year (y) follow-up (FU) of CheckMate 649
Authors
L.S. Wyrwicz,
K. ShitaraMarkus Moehler,
Jaffer Ajani,
Lijun Shen,
Marcelo Garrido,
Cristián Araneda,
Kensei Yamaguchi,
J. Cleary,
Elena Elimova,
Ricardo Brugés,
Michalis Karamouzis,
Tomasz Skoczylas,
Arinilda Bragagnoli,
T. Liu,
Mustapha Tehfé,
Kynan Feeney,
R. Wang,
J. Zhang +17 authors
,
Yelena Janjigian Tip Tip